For full details of each session, please view the event guide.

8:30 am

Morning Coffee

9:15 am Chair’s Opening Remarks

3D/Ex Vivo Models

9:30 am Improving the Safety Predictability of IO Modalities with Organ on Chip (OoC) Models

Synopsis

• Incorporating new OoC models in IO workflow: Key aspects to consider
• How to use OoC for Efficacy Models in IO
• Challenges in safety prediction in IO and how OoC can help
• High level overview of the regulatory status regarding using OoC based IO data in submission

10:00 am Round Table Discussions:

Synopsis

Discover multiple perspectives on the key issues in preclinical development. Join a roundtable discussion that
has been specifically designed to enable you to leave with insights that you can immediately implement into
your preclinical model strategies

Challenges in the scale-up and wider adoption of organoid models

How familiar should preclinical scientists be with Regulatory concepts? What should be considered in preclinical study design

Will isoform-specific detection and targeting in different tumour subtypes result into a further developed personalized Medicine?

10:45 am

Speed Networking & Morning Break

In Vitro Assays

11:45 am Session Reserved For Ocello

12:00 pm RNA-Sequencing Analysis of Immunotherapy Response in Organotypic Tumor Spheroids

  • David Barbie Associate Director, Dana Faber cancer institute

Synopsis

• Bulk RNA-sequencing (RNA-seq) uncovers dynamic responses to interferon-gamma versus PD-1 blockade in murine organotypic spheroids
• Development of methods to extract cells and perform single cell RNAseq refines this analysis
• These high resolution ex vivo functional studies help to uncover novel immunobiology

12:30 pm RG OncoRat – An Immunodeficient Rat Model to Compliment Your Oncology Programme

  • Tseten Jamling Vice President of Research & Development, Hera Labs Inc

Synopsis

• Novel immunodeficient rat model that demonstrates superior human tumor development efficiency and growth kinetics compared to similar mouse models
• Larger blood volume and tumor size allow for serial blood and core biopsy sampling for PK/PD analyses
• Potential for humanizing the immune system for immuno-oncology studies

12:45 pm

Networking Lunch

1:45 pm Panel Discussion: To What Extent Will Ex-Vivo Platform Replace In-Vivo Models From Technical, Ethical, and Regulatory Standpoints?

2:30 pm Improving Therapy and Stratification by Listening to Mitochondria

  • Anthony Letai Professor of Medicine, Dana Faber cancer institute

Synopsis

• If you want your drug to work in cancer, it has to kill the cancer cell
• Mitochondria decide whether or not the cancer cell dies via apoptosis
• BH3 profiling predicts whether apoptosis will occur

Supporting Techniques in Evaluating Therapeutic Response

3:00 pm Imaging of PD-L1 in Head and Neck Cancer in Response to Oncolytic Virotherapy

3:30 pm PK/PD from Drug Discovery to Registration: An Industry Case Study

  • Sonya Chapman Senior PK/PD Project Leader , Eli Lilly and Company

Synopsis

– PK/PD is a key tool in drug discovery and development

– Pre-clinical PK/PD knowledge is continually informative through compound identification, dose projection, clinical study designs and drug registration

– Establishing efficacious concentrations early helps to design molecules with high potential

4:00 pm Chair’s Closing Remarks

4:15 pm End of Day 2

For full details of each session, please view the event guide.